Loading the security overview…
Where the tokens are
None held
2 tokenized versions from 2 issuers
See every versionNo venues yet
No vault or pool we index takes these tokens.
PerpsNo markets
No Hyperliquid venue lists a GILD perp.
Where the tokens are
Key statistics
technicals as of Oct 2, 2026- Market cap
- $182.89B
- P/E
- —EPS -$2.61
- 52-week range
- $108.46 – $157.29price at 74% of range
- Volume
- 2.85Maverage day 5.73M
- Previous close
- $147.50
- P/S
- 6.0
- P/B
- 15.5
- Dividend yield
- 2.22%$3.28 a year
- Next ex-dividend
- —
- Next earnings
- Oct 29after the close
- Beta
- 0.1190 days, against SPY
- RSI (14)
- 43.8as of Oct 2
Figures describe Gilead Sciences shares, not any token.
Every tokenized version
Search and filter all tokensEach row is one issuer’s token for Gilead Sciences, with the chains it is deployed on. A bold chain is one where these wallets hold a balance. Tokens are not shares: no issuer in the registry publishes a shares-per-token ratio, so a balance is counted one per share and marked where that assumption is doing work.
About Gilead Sciences Inc
gilead.comGilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
- Type
- Common stock
- Sector
- Healthcare › Pharmaceuticals
- Exchange
- Nasdaq
- Listed since
- Jan 22, 1992
- Shares outstanding
- 1.24B
- Employees
- 17,000
Themes
Biotech - Drug Development › Infectious Disease & VaccinesHealthcare - Oncology › Cell & Gene Therapy for Cancer
Companies sharing these themesAs the market data provider names it. Where that differs from the issuers’ name for the security, both are shown so the difference is visible.
